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Abstract: Hyperthyroidism is one of the main endocrinopathies during pregnancy. The aim of this project was to identify 
the degree of control of hyperthyroid pregnant women based on the recommendations of the American Thyroid Association 
(ATA) in a real situation without the availability of propylthiouracil. This was a descriptive, retrospective and longitudinal 
study, including medical files of pregnant women with hyperthyroidism between 18 and 35 years. They were classified as 
having "Adequate" control if their thyroid profiles were within the recommendations of the ATA and had no adrenergic 
symptoms; and were categorized as having "Inadequate" control if they were not stabilized with monotherapy, or if they 
required high doses of antithyroid drugs or beta-blockers or showed serious complications including the need of an Intensive 
Care Unit (ICU) for mothers or neonates. The Chi square test was performed between treatment groups during the third 
trimester and the complications of pregnant women or neonates. A total of 173 hyperthyroid pregnant women were studied 
with an average age of 21 ± 4.7 years. Of the 33 patients with hyperthyroidism who received monotherapy with methimazole 
until the end of pregnancy, 23 (69.69%) were classified as having "Adequate" control. In a real life situation there is delay in 
the diagnosis of hyperthyroidism during pregnancy but even without propylthiuracil, an “Adequate” control can be reached in 
up to 20.53% of cases based on a methimazole monotherapy. 
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1. Introduction 
Hyperthyroidism is the second most common thyroid 
disease during pregnancy, with an incidence ranging from 0.1 
to 0.4% [1]. The most frequent cause of hyperthyroidism in 
pregnancy is Graves' disease (85-90% of cases) [2]. Among 
other causes are simple toxic adenoma, multinodular toxic 
goiter and thyroiditis, in addition to considering the cases of 
transient gestational thyrotoxicosis [3]. The diagnosis of this 
entity is usually a challenge for doctors in its initial phase 
due to the physiological changes of pregnancy [4]. 
The treatment options for hyperthyroidism are 
propylthiouracil (PTU), methimazole and carbimazole; 
occasionally it is recommended to add beta-blockers and 
subtotal thyroidectomy is reserved for specific cases [5]. 
Both PTU and methimazole may be associated with 
adverse events in embryological development [6]. However, 
the first is the drug of choice during the first trimester of 
pregnancy [7, 8] with the recommended initial dose of 200 to 
400 mg/day divided into three doses, while for methimazole 
it is 20 to 30 mg/day divided into two doses [9]. 
Improvement is usually observed within a week, however, it 
may take 4 to 6 weeks to get the full effect. Unfortunately 
PTU is not available in several countries. 
Beta-blockers are useful for controlling tachycardia or 
palpitations, although it is preferable to give short periods of 
treatment and even avoid their use due to increased chances 
of cardiovascular defects, cleft lip/palate and neural tube 
defects [10], although more recent studies with a large 
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number of patients do not confirm an increased risk of 
complications with these drugs [11]. 
The aim of this study was to describe the degree of control 
of hyperthyroid pregnant women treated with methimazole 




This descriptive, retrospective and longitudinal study was 
conducted at the "Mónica Pretelini Sáenz" Maternal-Perinatal 
Hospital (HMPMPS), Health Institute of the State of Mexico 
(ISEM), Toluca, Mexico. 
2.2. Patients 
The information was obtained from the clinical files and 
from the electronic data of the Department of Statistics. The 
inclusion criteria were: hyperthyroid pregnant women aged 
between 18 and 35 years who attended in the period 2010-
2016. Hyperthyroid patients with another accompanying 
comorbidity, who ingested antidepressants/antipsychotics or 
with abandonment of treatment or termination of pregnancy 
in another institution, were excluded. 
For the calculation of Body Mass Index (BMI = kg/m
2
), 
weight and height data were taken during the initial stage of 
pregnancy. Patients were classified as having "Adequate" 
control if their thyroid profiles were within the 
recommendations of the American Thyroid Association 
(ATA) for pregnant women without adrenergic symptoms, 
and were categorized as having "Inadequate" control if they 
were difficult to control based on monotherapy, if they 
required high doses of antithyroid drugs or beta-blockers or if 
mothers or neonates had serious complications, including 
admission to the Intensive Care Unit (ICU). 
2.3. Statistical Analysis 
The information was recorded in an Excel sheet, and 
measures of central tendency were calculated for the 
quantitative variables; for the qualitative variables, 
frequencies and percentages were used. Chi square test 
was performed between treatment groups during the third 
trimester and the complications of pregnant women and 
neonates. A p-value of less than 0.05 was considered 
statistically significant using the IBM SPSS Statistics 
23.0. 
2.4. Ethical Standards 
This study was approved by the Research and Research 
Ethics Committees of the HMPMPS (code 2016-09-479). 
This was considered a no-risk study, which followed the 
regulations of the Mexican General Health Law in Matters of 
Research and complied with the standards of the Declaration 
of Helsinki (updated in Fortaleza, Brazil, 2013). 
3. Results 
We studied a total of 173 hyperthyroid pregnant women 
who met the criteria. The mean age was 21 ± 4.7 years, 
weight 79 ± 3.9 kg and height 1.56 ± 0.02 cm. According to 
the BMI classification, the following data were obtained: 
Overweight: 18 (10.40%) patients, Obesity grade I: 136 
(78.61%) and Obesity grade II: 19 (10.98%). 
Table 1 shows the thyroid-stimulating hormone (TSH), 
triiodothyronine (T3) and thyroxine (T4) values obtained per 
trimester. When calculating the 2.5 and 97.5 percentiles of 
TSH, the values per trimester were: 0.04-2.79 mU/L, 0.032-
3.93 mU/L, and 0.008-2.804 mU/L. 
Table 1. Values of thyroid hormones per trimester. 
 
Trimester Mean Median Mode 
Standard 
Deviation 
TSH (mU/L) First1 1.21 1.03 0.97 0.77 
 
Second2 1.68 1.55 0.89 1.19 
 
Third3 1.21 1.15 0.89 0.78 
Free T4 (ng/dl) First1 1.59 1.38 1.23 0.82 
 
Second2 4.25 4.33 4.56 0.81 
 
Third3 2.47 1.66 1.23 1.42 
Free T3 (pg/ml) First1 3.59 3.6 3.44 0.78 
 
Second2 3.48 3.53 3.01 0.84 
 
Third3 3.68 3.47 3.45 0.96 
1First trimester: 0-12 weeks of gestation. 
2Second trimester: 13-28 weeks of gestation. 
3Third trimester: 29-40 weeks of gestation. 
Only 26 (15.02%) pregnant women were diagnosed with 
hyperthyroidism during the first trimester. From this initial 
number of cases, 17 (65.38%) were in treatment with 
methimazole + propranolol of which the most frequent doses 
were 45 mg/24h of the first and 40 mg/24h of the second 
divided into three doses, while nine (34.61%) received 
monotherapy with propranolol at a dose of 40 mg/24 h. 
During the second trimester, all the 173 pregnant women 
were diagnosed with hyperthyroidism. At this cut-off point 
the most frequent treatment option was methimazole as 
monotherapy, used in 112 (64.7%) of the pregnant women, 
with the most frequent doses being 30 mg/24h in 30 (17.34%) 
patients, and 40 mg/24h in 29 (16.76%) patients; 20 mg/24h 
was prescribed only in 20 (11.56%) patients and often less, 
other doses. 
Of the 112 patients on monotherapy with methimazole 
during the second trimester, an adjustment to 
methimazole/metoprolol in 27 (24.10%) patients and 
methimazole/propranolol in 52 (46.42%) was documented. 
Only 33 (29.46%) continued with methimazole monotherapy 
until the end of pregnancy, most of them requiring a dose 
increase in the third trimester of up to 50 mg/24h; from this 
subgroup, 23 (69.69%) were classified as having "Adequate" 
control and 10 (30.30%) as "Inadequate" control. Maternal 
complications were uterine atony in three patients, and others 
were premature rupture of membranes, preeclampsia, and 
admission to the ICU. For the neonates the most common 
complications were neonatal sepsis, fetal tachycardia and low 
weight for gestational age. 
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Only 13 (7.5%) women were treated with propranolol 
monotherapy at a dose of 80 mg/24h in 10 of them and 40 
mg/24h in three. Two pregnant women continued with 
propranolol at a dose of 80 mg/24h – 20 mg/24h, 
highlighting the finding that both had premature rupture of 
membranes. Eight patients who started on monotherapy with 
propranolol, changed the drug to methimazole monotherapy 
at a dose of 40 mg/24h, and three were admitted to the ICU. 
Three patients who started propranolol monotherapy finished 
gestation with two-drug therapy: methimazole/metoprolol in 
doses of 20 mg/24h – 60 mg/24h and 
methimazole/propranolol in doses of 45 mg/24h – 40 mg/24h 
with unfavorable results. 
Of the patients under treatment with methimazole, there 
were five cases of each of the following complications: 
admission to the ICU, preeclampsia and uterine atony; the 
others (23) had no complications. 28 of the neonates had no 
complications, but 13 had low weight for gestational age. Of 
the pregnant women with treatment based on 
methimazole/metoprolol, seven were admitted to the ICU, 
four developed gestational diabetes and two had 
preeclampsia. Of the pregnant women with treatment based 
on methimazole/propranolol, 13 developed preeclampsia and 
11 were admitted to the ICU. 
During the third trimester the different treatments did not 
have an important significance with the degree of control 
obtained. In that trimester, of a total of 81 patients on 
treatment with methimazole/propranolol 48 achieved the 
TSH ranges of the ATA. 
Within the full population and in decreasing order, the 
complications were preeclampsia: 11.6%, uterine atony: 
9.2%, premature rupture of membranes: 6.9%, gestational 
diabetes: 6.4% and abdominal resolution: 5.8%. Caesarean 
section resolution is not considered a complication, however, 
most of the times it was preceded by complications such as 
premature rupture of membranes, oligohydramnios, and fetal 
distress, among others. 
With regard to neonates, the most frequent complications 
were the following: low weight for gestational age in 24 
(13.9%); neonatal sepsis in 9.8% with predominantly a 
pulmonary focus; prematurity in 9.2%, reported as late 
preterm (34-36.6 weeks of gestation according to the WHO) 
in most of them, fetal tachycardia in 6.4%, cardiac pathology 
in 5.2%, severe oligohydramnios (amniotic fluid index <5 cm 
according to Phelan) in 4.6%; admission to the ICU in 2.3%, 
and stillbirth in one unfortunate case. 
A Chi square test was performed between treatment groups 
during the third trimester without finding significant 
differences when comparing the groups, inferring that the 
treatment used during the third trimester influences neither 
the complications of pregnant women nor in newborns. 
4. Discussion 
Generally speaking, our population reflects a problem in 
Mexico with a tendency for pregnancies in adolescents; in 
fact, most of our patients were already secundigravidas or 
even multigravidas [12], and the majority of them during the 
first trimester had a BMI classified as Obesity grade I, 
remembering that Mexico ranks in the first positions for 
obesity [13]. Both conditions increase the risk of 
complications [12, 14]. 
Currently, despite the fact that hyperthyroidism constitutes 
a challenge for clinical diagnosis due to the masked 
symptoms of pregnancy itself [15], in several countries, 
including Mexico, the determination of thyroid hormones in 
pregnant women is not included in the prenatal control. This 
a critical issue to be attended to and even more so during the 
first trimester since in this period the fetus depends on the 
maternal hormones [16]. 
In our study, TSH values less than 0.2 mU/L belonged to 
pregnant women who had already been diagnosed with 
hyperthyroidism during the first trimester, and those with 
values greater than 2.5 mU/L (13 women) never presented 
adequate values, despite treatment in high doses. The values 
of T4, compared with the reference values of the HMPMPS 
laboratory were totally out of range, with extremely high 
values, even more than those described in several 
international studies [17, 18]. In the case of T3, the values 
obtained were very similar to the limits of the reference 
laboratory. 
It was also found in the population studied, that during the 
second trimester, the behavior of the thyroid hormones was 
above those of the laboratory of reference. Thus, according to 
the values of thyroid function during the second trimester, 
showing in general a higher decontrol required higher doses 
of monotherapy or the use of a two-drug therapy. In the third 
trimester, a behavior like that described in the two previous 
trimesters was observed, with very high T4L values, which 
speak to us of a control much lower than expected in this 
period. 
The reference values of thyroid hormones in the general 
population are not similar to those of the pregnant women 
[19]. The above, in clinical practice, can lead to results 
misinterpretation, so it is convenient to define the values of 
thyroid hormones in the population of pregnant women in 
each trimester and for each area of origin, to make an early 
and correct diagnosis and to offer the best treatment. It must 
be emphasized that failure to diagnose thyroid disease in a 
timely manner may clinically manifest as a thyrotoxicosis 
with potential life risk for the maternal-fetal binomial [20]. 
Finally, it is noteworthy that "Adequate" control was 
achieved in 20.53% of cases based on an initial methimazole 
monotherapy of 112 patients starting this treatment in the 
second trimester of pregnancy. Furthermore, although the 
European and American guidelines mention that the thyroid 
control of pregnant women should be carried out every 2 to 6 
weeks [21], this is impossible in the case of health 
institutions that serve a very low socioeconomic level 
population. 
A matter of great concern is the risk of embryopathies 
with either option, propylthiouracil or methimazole, widely 
reported in the literature [22, 23]. Although this project was 
not designed to get either odds ratio or relative risk 
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calculations of cardiac anomalies while using methimazole, 
the presence of a cardiac pathology in 5.2% of the 
newborns of the full sample could reflect a trend of a higher 
rate of congenital cardiac defects than that reported for the 
same population of 7.4 per 1,000 live births (35.6 per 1,000 
in preterm infants and 3.68 per 1,000 in term newborns) 
[24]. 
Our results prove that the focus, to avoid pregnancy 
complications in cases of hyperthyroidism, must be on the 
preconception orientation, offering to future mothers who 
have the diagnosis of hyperthyroidism to receive at least six 
months before pregnancy a dose of radioactive iodine to 
convert them into hypothyroidism, which has less risks to the 
mother and the fetus [25]. 
A limitation of this study is that there may be an 
underdiagnoses of hyperthyroidism cases, since in the 
electronic file of the Department of Statistics this diagnosis 
may not have been registered if the patient entered the 
hospital for another reason. 
Two main conclusions are obtained based on the results of 
this study. First, the cases of hyperthyroidism that debut in 
pregnancy are still delayed in the diagnosis during the first 
trimester. Second, in a real life situation “Adequate” control 
can be reached in only 13.29% of hyperthyroidism cases 
during pregnancy based on a methimazole monotherapy. 
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